Article info

Download PDFPDF

Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy

Authors

  • Damian Jaggi Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Thanoosha Nagamany Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Andreas Ebneter Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Marion Munk Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland Bern Photographic Reading Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Sebastian Wolf Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland Bern Photographic Reading Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Martin Zinkernagel Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland Bern Photographic Reading Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  1. Correspondence to Martin Zinkernagel, University Hospital Bern, Bern 3010, Switzerland; Martin.zinkernagel{at}insel.ch
View Full Text

Citation

Jaggi D, Nagamany T, Ebneter A, et al
Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy

Publication history

  • Received April 19, 2020
  • Revised August 20, 2020
  • Accepted October 11, 2020
  • First published October 30, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.